There is on-going development of generic EU CTD Dossier of Azithromycin dihydrate, tablets, 250/500 mg.
DCP slots will be available in November 2009.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Azithromycin is used to treat or prevent certain bacterial infections, most often those causing middle ear infections, tonsillitis, throat infections, laryngitis, bronchitis, pneumonia, Typhoid, yeast infections, and sinusitis. In recent years it has primarily been used to prevent bacterial infections in infants and those with weaker immune systems. It is also effective against certain urinary tract infections, such as non-gonococcal urethritis and cervicitis. Recent studies have also indicated it to be effective against late-onset asthma, but these findings are controversial and not widely accepted.
More details at: http://www.rxlist.com/zithromax-drug.htm.
|Pharma licensing||Out-licensing (offer)|